Ottawa, Ontario — November 19, 2025 — Leads & Copy — Innovative Medicines Canada (IMC) has announced the appointment of Gaby Bourbara, President of AstraZeneca Canada, as the new Chair of its Board of Directors. Bourbara brings over two decades of leadership within the Canadian and global biopharmaceutical sectors.
Dr. Bettina Hamelin, President & CEO of Innovative Medicines Canada, emphasized Bourbara’s collaborative approach and strong belief in science. She stated his leadership will support IMC and its members in continuing to advance patient care and strengthen Canada’s health and economic landscape.
As Chair, Bourbara will guide IMC’s efforts to speed up patient access to new medicines and vaccines. He will also work to ensure the life sciences sector remains a key element of Canada’s economic growth.
Bourbara said he is honored to assume this role at such an important time for the pharmaceutical industry. He emphasized the need to build on Canada’s solid foundation of research and talent by fostering partnerships between government, clinicians, and patient communities. His aim is to accelerate the delivery of new treatments to patients and create a stronger environment for research and investment.
Bourbara is taking over the position from Brigitte Nolet, President & CEO of Roche Canada Pharma, who served as Chair from 2023 to 2025.
Innovative Medicines Canada is the national association representing Canada’s innovative pharmaceutical industry. It promotes policies that support the discovery, development, and delivery of innovative medicines and vaccines. IMC and its members are committed to being trusted partners within Canada’s healthcare system.
IMC members invest $3.2 billion in R&D annually, which contributes $18.4 billion per year to Canada’s knowledge-based economy.
Guided by a code of ethical practices, IMC members collaborate with governments, private payers, healthcare professionals, and other stakeholders.
Source: Innovative Medicines Canada
